Sanofi, Medivation Start Takeover Talks
July 05 2016 - 4:33PM
Dow Jones News
By Noemie Bisserbe
PARIS -- French drugmaker Sanofi SA said Tuesday it had entered
takeover talks with U.S. biotech firm Medivation Inc. and increased
its offer to $58 per share.
Sanofi will offer an additional $3 per share in the form of a
contingent value right relating to the future sales of one of
Medivation's experimental drug -- a breast cancer treatment
currently in late stage of clinical trials.
The Paris-based drugmaker has been in pursuit of Medivation for
more than three months, in a bid to strengthen its new products
portfolio and build a competitive position in a hotly tipped market
in which it is still a small player.
Separately, Medivation said it has entered into confidentiality
agreements with a number of parties that have expressed interest in
exploring a potential transaction.
In May, Sanofi had called a shareholder vote on whether to
remove the entire board of the oncology drugmaker, after the U.S.
biotech firm's board rejected its $9.3 billion offer or $52.50 per
share. Sanofi said Tuesday that it had agreed to suspend the
vote.
--Ezequiel Minaya contributed to this article.
Write to Noemie Bisserbe at noemie.bisserbe@wsj.com
(END) Dow Jones Newswires
July 05, 2016 17:18 ET (21:18 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From Apr 2024 to May 2024
Medivation, Inc. (MM) (NASDAQ:MDVN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Medivation, Inc. (MM) (NASDAQ): 0 recent articles
More Medivation, Inc. (MM) News Articles